

Mother's details

## **Neonatal BCG Assessment**

| Name.                                                                                                                                                                                                         | Home:   |        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------|
| Address:                                                                                                                                                                                                      | Mobile: |        |
| NHI:                                                                                                                                                                                                          |         |        |
| Email address:                                                                                                                                                                                                |         |        |
| All newborns must be assessed for eligibility.                                                                                                                                                                |         |        |
| All eligible babies must be offered neonatal BCG vaccine                                                                                                                                                      |         |        |
| ELIGIBILITY SCREEN (by LMC)                                                                                                                                                                                   |         |        |
| If the answer is <b>yes</b> to any of the below questions then the baby is at risk of                                                                                                                         |         | ✓= YES |
| exposure to TB. Neonatal <b>BCG</b> is recommended for this baby unless there are contraindications* to BCG vaccination.                                                                                      |         | × = NO |
| A. Will the baby be living in a house or family/whanau with a person who currently has TB or has a past history of TB?                                                                                        |         |        |
| B. Does the baby have one or both parents or household members who, within the last five years, lived for a period of six months or more in countries with high numbers of TB? PTO for country details        |         |        |
| If yes, list country/countries:                                                                                                                                                                               |         |        |
| C. Will the baby, during the first five years of life, be living for three months or longer in a country with high numbers of TB and is likely to be exposed to those with TB? <i>PTO for country details</i> |         |        |
| If yes, list country/countries:                                                                                                                                                                               |         |        |
| Staff Name Staff Signature                                                                                                                                                                                    |         | Date   |
|                                                                                                                                                                                                               |         |        |

**Contact numbers** 

baby shown to be HIV negative at 12-15 months of age), immunosuppressive treatments (in baby, or in mother during pregnancy e.g. biologic agents such as TNF alpha blockers - BCG contraindicated until baby is 8-9 months old), baby exposed to infectious TB case (BCG contraindicated until baby has been investigated for TB infection).

\* Contraindications include malignant conditions, immune compromising conditions (including maternal HIV – BCG is contraindicated until

Email completed form to ARPHS: <a href="mailto:bcg@adhb.govt.nz">bcg@adhb.govt.nz</a> or Fax completed form to ARPHS: 09 630 7431: Attention BCG Programme

## Countries with TB incidence of ≥ 40 per 100,000 population

**Pakistan** Afghanistan Ghana Greenland Palau Algeria Angola Guam Panama

Guinea Papua New Guinea Azerbaijan

Guinea-Bissau **Paraguay** Bangladesh Benin Guyana Peru Haiti **Philippines** Bhutan India Republic of Korea Bolivia (Plurinational Indonesia Republic of Moldova State of)

Romania Botswana Iraq

Russian Federation Brazil Kazakhstan

Brunei Darussalam Kenya Rwanda

Burkina Faso Kiribati São Tomé and Príncipe

Burundi Senegal Kyrgyzstan Cabo Verde Lao People's Democratic Sierra Leone Cambodia Republic Singapore Cameroon Lesotho Solomon Islands

Somalia Central African Republic Liberia South Africa Chad Libya South Sudan China Lithuania China, Hong Kong SAR Madagascar Sri Lanka China, Macao SAR Malawi Sudan Congo Malaysia **Tajikistan** Mali **Thailand** Côte d'Ivoire **Democratic People's** Marshall Islands Timor-Leste Republic of Korea Mauritania Turkmenistan

Democratic Republic of the Micronesia Tuvalu Congo (Federated States of) Uganda Djibouti Mongolia Ukraine

Dominican Republic Morocco United Republic of Tanzania

Ecuador Mozambique Uzbekistan El Salvador Myanmar Vanuatu **Equatorial Guinea** Namibia Venezuela

Eritrea Nauru (Bolivarian Republic of)

Eswatini Viet Nam Nepal Ethiopia Nicaragua Yemen Fiji Niger Zambia Gabon Nigeria Zimbabwe

Gambia Niue

Georgia Northern Mariana Islands

Source: Immunisation handbook 2017. Appendix 8.

https://www.health.govt.nz/system/files/documents/publications/immunisation-handbook-2017-2nd-edition-mar2018v8.html# Toc21503269

Last updated 29 June 2020

